Literature DB >> 31228813

Adenovirus-mediated down-regulation of miR-21-5p alleviates experimental autoimmune uveoretinitis in mice.

Long Shi1, Hui Guo1, Ziwei Li2, Yuwei Wang2, Yuanjian Wang3, Yan Cui4.   

Abstract

MiR-21-5p has been found to be up-regulated in the retina of experimental autoimmune uveoretinitis (EAU) mice and correlated with the pathogenesis of EAU. The objective of the present study is to explore the role of miR-21-5p in EAU. C57 mice were immunized with residue1-20 (IRBP1-20) in complete Freund's adjuvant supplemented with Mycobacterium tuberculosis H37Ra to induce EAU, and miR-21-5p was knocked down via subretinal injection of anti-miR-21-5p adenovirus. The pathological score, TUNEL positive cells and the expression of pro-inflammatory factors in the retina were reduced, and the expression of IL-10 was increased by down-regulation of miR-21-5p. Up-regulation of miR-21-5p significantly decreased the mRNA and protein levels of IL-10 in ARPE-19 cells. The binding activity of miR-21-5p on the 3'UTR of IL-10 mRNA was confirmed by luciferase reporter assay. Moreover, the miR-21-5p level in splenic lymphocytes of EAU mice was increased at the 7th day after immunization and reached its peak at the 14th day, that was in accordance with the changing trend with the Th17 cell frequency in the spleen. Besides, lentivirus-mediated down-regulation of miR-21-5p reduced the Th17 cell frequency and increased the Treg cell fraction of IRBP1-20-stimulated lymphocytes in vitro. Taken together, in situ down-regulation of miR-21-5p attenuates EAU by inhibiting inflammatory responses and reducing retinal cell apoptosis. miR-21-5p may also participate in the progress of EAU by affecting Th17/Treg balance via the regulation of IL-10. Therefore, we demonstrate that miR-21-5p can serve as a therapeutic target in the management of uveitis and other autoimmune diseases.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Experimental autoimmune uveoretinitis; IL-10; Inflammatory; Th17; Treg; miR-21-5p

Mesh:

Substances:

Year:  2019        PMID: 31228813     DOI: 10.1016/j.intimp.2019.105698

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  7 in total

1.  Tregs in Autoimmune Uveitis.

Authors:  Zhaohao Huang; Wenli Li; Wenru Su
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  miRNAs Alter T Helper 17 Cell Fate in the Pathogenesis of Autoimmune Diseases.

Authors:  Junxia Huang; Xinzhi Xu; Ji Yang
Journal:  Front Immunol       Date:  2021-04-21       Impact factor: 7.561

3.  MicroRNA-21 Regulates Diametrically Opposed Biological Functions of Regulatory T Cells.

Authors:  Jijun Sun; Ruiling Liu; Xiaozhen He; Jiang Bian; Wenbo Zhao; Weiyun Shi; Qingguo Ruan
Journal:  Front Immunol       Date:  2021-11-11       Impact factor: 7.561

4.  MicroRNAs in the regulation of Th17/Treg homeostasis and their potential role in uveitis.

Authors:  Fen Tang; Zhou Zhou; Kongqian Huang; Wen Deng; Jiali Lin; Ruoyun Chen; Min Li; Fan Xu
Journal:  Front Genet       Date:  2022-09-14       Impact factor: 4.772

5.  Chandipura virus dysregulates the expression of hsa-miR-21-5p to activate NF-κB in human microglial cells.

Authors:  Neha Pandey; Meghana Rastogi; Sunit K Singh
Journal:  J Biomed Sci       Date:  2021-07-07       Impact factor: 8.410

6.  Photoreceptor protection by mesenchymal stem cell transplantation identifies exosomal MiR-21 as a therapeutic for retinal degeneration.

Authors:  Chun-Lei Deng; Cheng-Biao Hu; Sheng-Tao Ling; Na Zhao; Li-Hui Bao; Feng Zhou; Ye-Cheng Xiong; Tao Chen; Bing-Dong Sui; Xiao-Rui Yu; Cheng-Hu Hu
Journal:  Cell Death Differ       Date:  2020-10-20       Impact factor: 15.828

7.  miRNA-21 regulates CD69 and IL-10 expression in canine leishmaniasis.

Authors:  Jaqueline Poleto Bragato; Gabriela Torres Rebech; Jéssica Henrique de Freitas; Marilene Oliveira Dos Santos; Sidnei Ferro Costa; Flavia de Rezende Eugênio; Paulo Sérgio Patto Dos Santos; Valéria Marçal Felix de Lima
Journal:  PLoS One       Date:  2022-03-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.